Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03847636
Other study ID # IRB00163804
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 13, 2019
Est. completion date May 2026

Study information

Verified date May 2024
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multicenter prospective non-randomized interventional study (clinical trial) that will assess the safety and efficacy of cryoballoon ablation treatment using the C2 Cryoballoon device (Pentax Medical Corporation) as an alternative primary treatment modality for sporadic and familial nonampullary nonpolypoid (flat) duodenal adenomas.


Description:

Duodenal adenomas are precursors to adenocarcinoma. Treatment with endoscopic polypectomy is technically challenging problematic and associated with a high rate of complication - overall 26%, with bleeding 22-40%, higher with larger polyps. Surgery to remove these benign polyps would be a Whipple operation, which has a high morbidity and 1-4% mortality rate. Medical therapies like celecoxib decrease the number of polyps but do not prevent cancer. This multicenter prospective cohort study will assess the safety and efficacy of cryoablation treatment as an alternative primary treatment modality for sporadic and familial nonampullary nonpolypoid (flat) duodenal adenomas Prospective studies have demonstrated the safety and efficacy of nitrous oxide focal cryoballoon ablation for complete eradication of Barrett's esophagus (including a clinical trial published by the Principal Investigator), which is intestinal metaplasia, which is histologically similar to normal duodenal mucosa. When inflated, the cryoballoon flattens the duodenal folds allowing improved visibility of the duodenal lesions. The focal ablation allows precise targeting and avoidance of the ampulla to minimize pancreatitis risk. Two cases at Johns Hopkins Hospital have been treated successfully and safely using cryogen dose of 10 seconds. The procedures were easy and short, with excellent views of the lesion with balloon inflation and high definition endoscope. No major adverse events, pain requiring treatment, or bleeding were noted. Minor adverse events included transient abdominal bloating lasting for < 3 days in 1 patient. In one patient with sporadic laterally spreading large Paris 2A polyp who declined standard treatments, complete eradication was achieved with 2 ablation sessions. In the other patient with familial adenomatous polyposis (FAP) who had 2 hospitalizations for post-polypectomy bleeding after duodenal EMR, complete eradication was noted after 1 treatment of 3 Paris 2A and 2B adjacent polyps. Follow-up of these two patients shows no recurrence > 1 year and at the most recent follow-up procedures. Clinical and endoscopic surveillance continues. In addition, another physician at the University of Texas Health Science Center at San Antonio (UTHSCSA) reported another two patients with duodenal adenomas in her practice treated successfully with cryoballoon ablation without complications. Two other collaborating physicians at Memorial Hermann Texas Medical Center in Houston, Texas, and Geisinger Medical Center in Pennsylvania have also reported favorable response of these challenging neoplasms to endoscopic cryoballoon ablation. The group is currently preparing a case series report and a separate Institutional Review Board application is being submitted. This study may impact on the management of patients with duodenal adenomas by demonstrating the potential for safe and effective non-operative eradication using cryoballoon ablation. The safety profile of endoscopic cryoballoon ablation is likely to be better than endoscopic resection based on a large clinical and research experience in Barrett's esophagus patients (>250) and small clinical experience in duodenal adenoma patients, with <=5% bleeding, no perforation, and transient, mild post-treatment discomfort.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date May 2026
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Sporadic duodenal adenomas between 1 to 5 cm in widest diameter - FAP patient with Spigelman class 2, 3 or 4 (see definition below) - Polyp characteristics: Non-polypoid lesions Paris 2A and 2B, or - Sessile adenomas, occupying no more than 50% circumference of duodenum, and no more than 3 duodenal folds - Individuals must be considered high risk for surgery or endoscopic resection, due to complication risk, or declined standard therapies. - Prior endoscopic mucosal resection (EMR) or saline-assisted polypectomy allowed if polyp characteristics meet inclusion criteria. Exclusion Criteria: - Suspected or proven duodenal carcinoma - Paris 1p pedunculated, Paris 2c, or 3 lesions - Paris 1s lesion > 4 mm thick (estimated with closed biopsy forceps) - Ampullary lesion or lesion involving the ampulla - Prior failed ablative treatment with Argon Plasma Coagulation, laser, or cryotherapy - Pre-existing esophageal, gastric, pyloric, or duodenal stenosis/stricture preventing advancement of a therapeutic endoscope during screening/baseline esophagogastroduodenoscopy (EGD.) Subjects are eligible if the stenosis/stricture is dilated to at least 15mm, but baseline treatment may need to be delayed. - Any endoscopically-visualized abnormalities such as ulcers, masses or nodules during screening/baseline EGD within 3 cm of the treatment area. - Subjects with nodular polyps or suspicion of invasive cancer by white light endoscopy /enhanced imaging/biopsy identified during screening/baseline EGD - Suspicion of malignancy by abdominal or endoscopic ultrasound imaging based on malignant lymph nodes, invasion of lesion beyond mucosa. - EMR or polypectomy < 6 weeks prior to baseline treatment. - Untreated invasive esophageal malignancy, including margin-positive EMR. - Active duodenitis in treatment zone during screening/baseline EGD. - Severe medical comorbidities precluding endoscopy, or limiting life expectancy to less than 2 years in the judgment of the endoscopist. - Uncontrolled coagulopathy or inability to be off anticoagulation or anti-platelet medication per standards of the institutions performing cryoablation. - Known portal hypertension, visible esophageal, gastric, or duodenal varices, or history of varices. - General poor health, multiple co-morbidities placing the patient at risk, or otherwise unsuitable for trial participation. - Pregnant or planning to become pregnant during period of study participation. - Patient refuses or is unable to provide written informed consent.

Study Design


Intervention

Device:
CryoBalloon ablation
Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.

Locations

Country Name City State
United States Johns Hopkins Hospital Baltimore Maryland
United States Methodist Dallas Medical Center Dallas Texas
United States Geisinger Medical Center Danville Pennsylvania
United States Northwell Health Manhasset New York

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Pentax Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of cryoBalloon ablation in treating non-ampullary non-polypoid duodenal adenomas (DAs) as assessed by the incidence of adverse events in all treated patients To assess incidence of treatment-related adverse events following cryoablation using the C2 cryoballoon system, defined by frequency or number of adverse events in all treated patients (per patient analysis). 5 years
Primary Safety of cryoBalloon ablation in treating non-ampullary non-polypoid duodenal adenomas (DAs) as assessed by the incidence of adverse events in all treatment procedures To assess incidence of treatment-related adverse events following cryoablation using the C2 cryoballoon system, defined by frequency or number of adverse events in all treatment procedures (per procedure analysis). 5 years
Primary Complete eradication rate of DAs Complete eradication (CE) rate of DAs as assessed by a combination of endoscopic and pathologic absence of adenomatous tissue in treated areas. 1 year
Secondary Percent change in the treated duodenal adenoma size Endoscopic assessment: percent change in adenoma size by blinded review by 3-person expert panel of still images with region of interest marked by tattoo - per lesion analysis and per patient analysis. Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Technical failure rate Technical failure rate is the proportion of treatment procedures with cryoballoon ablation that did not complete delivery of cryogen to all targeted sites. 5 years
Secondary Change in Spigelman class score Percent change in Spigelman classification for polyp burden in FAP patients from baseline to 1 year after treatment is completed. The Spigelman classification assigns points based upon polyp number, polyp size, histology and dysplasia grade, where Stage 0 = 0 points, Stage I = 1-4 points, Stage II = 5-6 points, Stage III = 7-8 points, and Stage IV = 9-12 points. The higher the score, the more severe or advanced the FAP disease in the duodenum. Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Progression rate to high grade dysplasia or duodenal cancer Progression rate: percentage of patients with progression of dysplasia grade to high grade dysplasia or invasive cancer, compared to baseline biopsies, at any time during the study. 5 years
Secondary Time to complete eradication of DAs in each patient Time to complete eradication (in months) of all duodenal adenomas in each patient 5 years
Secondary Time to complete eradication of each treated DA lesion Time to complete eradication (in months) of each treated DA lesion 5 years
Secondary Median number of CryoBalloon treatments to complete eradication. Median number of cryoballoon ablation treatments to achieve complete eradication. 5 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05630794 - Testing ONC201 to Prevent Colorectal Cancer Phase 1
Completed NCT02961374 - Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Phase 2
Completed NCT01483144 - Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Completed NCT00641147 - Curcumin in Treating Patients With Familial Adenomatous Polyposis Phase 2
Recruiting NCT03471403 - Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis
Not yet recruiting NCT04531930 - Colorectal Adenoma Canceration in FAP
Recruiting NCT04677998 - A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
Recruiting NCT04678011 - A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
Completed NCT00927485 - Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) N/A
Recruiting NCT00253812 - Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy N/A
Withdrawn NCT00248053 - Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients Phase 2
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Completed NCT04674228 - Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
Completed NCT01656746 - Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease N/A
Completed NCT00808743 - Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Phase 2/Phase 3
Not yet recruiting NCT05112822 - Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP) Phase 1
Recruiting NCT02656134 - Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) N/A
Withdrawn NCT01245816 - A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Recruiting NCT04709445 - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses N/A
Enrolling by invitation NCT05402891 - The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis Phase 2